鱼跃医疗
(002223)
| 流通市值：246.04亿 | | | 总市值：261.89亿 |
| 流通股本：9.34亿 | | | 总股本：9.95亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,569,315,559.46 | 2,370,366,154.18 | 7,955,022,614.76 | 6,544,895,742.68 |
| 营业收入 | 4,569,315,559.46 | 2,370,366,154.18 | 7,955,022,614.76 | 6,544,895,742.68 |
| 二、营业总成本 | 3,668,138,104.59 | 1,866,982,526.48 | 6,616,589,598.1 | 5,187,824,391.82 |
| 营业成本 | 2,293,672,533.98 | 1,180,164,309.42 | 3,930,042,261.81 | 3,249,593,235.42 |
| 税金及附加 | 42,450,416.55 | 22,326,740.29 | 76,397,429.33 | 62,066,173.32 |
| 销售费用 | 834,398,757.01 | 402,815,941.57 | 1,763,462,079.41 | 1,232,547,528.65 |
| 管理费用 | 226,354,161.08 | 110,547,207.98 | 475,517,451.17 | 339,196,375 |
| 研发费用 | 306,296,171.98 | 158,685,705.74 | 570,145,985.28 | 444,570,559.97 |
| 财务费用 | -35,033,936.01 | -7,557,378.52 | -198,975,608.9 | -140,149,480.54 |
| 其中:利息费用 | - | - | 5,997,356.94 | - |
| 其中:利息收入 | 119,864,759.74 | 48,107,693.6 | 249,182,104.77 | 172,420,498.89 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 18,236,442.79 | 2,271,021.41 | 34,149,903.34 | 34,974,001.74 |
| 资产处置收益 | -236,451.13 | -371,380.78 | 1,281,395.38 | 1,067,120.71 |
| 资产减值损失(新) | 1,557,761.33 | 141,611.71 | -29,634,938.18 | -9,624,422.43 |
| 信用减值损失(新) | -29,758,881.08 | -30,246,861.9 | -3,837,303.57 | -24,045,999.88 |
| 其他收益 | 67,163,578.04 | 26,114,710.86 | 359,928,878.71 | 325,588,275.08 |
| 营业利润平衡项目 | - | 0 | 0 | 0 |
| 四、营业利润 | 958,139,904.82 | 501,292,729 | 1,700,320,952.34 | 1,685,030,326.08 |
| 加:营业外收入 | 15,120,372.76 | 445,484.44 | 26,290,665.47 | 1,863,016.25 |
| 减:营业外支出 | 1,655,369.29 | 336,039.97 | 42,119,422.16 | 2,560,464.88 |
| 利润总额平衡项目 | - | 0 | 0 | 0 |
| 五、利润总额 | 971,604,908.29 | 501,402,173.47 | 1,684,492,195.65 | 1,684,332,877.45 |
| 减:所得税费用 | 123,735,865.06 | 72,190,934.45 | 200,355,944.78 | 218,034,227.66 |
| 六、净利润 | 847,869,043.23 | 429,211,239.02 | 1,484,136,250.87 | 1,466,298,649.79 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 847,869,043.23 | 429,211,239.02 | 1,484,136,250.87 | 1,466,298,649.79 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 842,813,546.32 | 428,328,475.91 | 1,481,794,880.13 | 1,466,043,552.13 |
| 少数股东损益 | 5,055,496.91 | 882,763.11 | 2,341,370.74 | 255,097.66 |
| 扣除非经常损益后的净利润 | 761,227,088.92 | 410,114,212.99 | 1,168,613,796.79 | 1,169,266,533.55 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.84 | 0.43 | 1.48 | 1.47 |
| (二)稀释每股收益 | 0.84 | 0.43 | 1.48 | 1.47 |
| 八、其他综合收益 | -28,429,681.41 | -21,770,602.63 | 98,208,788.57 | -25,254,882.74 |
| 归属于母公司股东的其他综合收益 | -26,871,694.91 | -20,954,061.59 | 95,069,868.13 | -28,877,933.06 |
| 九、综合收益总额 | 819,439,361.82 | 407,440,636.39 | 1,582,345,039.44 | 1,441,043,767.05 |
| 归属于母公司股东的综合收益总额 | 815,941,851.41 | 407,374,414.32 | 1,576,864,748.26 | 1,437,165,619.07 |
| 归属于少数股东的综合收益总额 | 3,497,510.41 | 66,222.07 | 5,480,291.18 | 3,878,147.98 |
| 公告日期 | 2026-08-22 | 2026-04-25 | 2026-04-25 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |